Pulmozyme
Payments companies reported to CMS as associated with Pulmozyme. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pulmozyme, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pulmozyme
These are the largest totals companies reported as associated with Pulmozyme. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Yuh Chin Huang | Durham, NC | Critical Care Medicine (Internal Medicine) | $124.90 |
| Jeong Yun | Boston, MA | Pulmonary Disease | $124.90 |
| Jennifer Alexander Brett | Saint Louis, MO | Pulmonary Disease | $124.90 |
| Yun Shim | Charlottesville, VA | Critical Care Medicine (Internal Medicine) | $124.90 |
| Samuel Louie | Sacramento, CA | Pulmonary Disease | $124.90 |
| Farrah Kheradmand | Houston, TX | Pulmonary Disease | $124.90 |
| Russell Bowler | Denver, CO | Pulmonary Disease | $124.90 |
| Anas Hadeh | Weston, FL | Pulmonary Disease | $124.90 |
| James Krings | Saint Louis, MO | Pulmonary Disease | $124.90 |
| David Mannino | Lexington, KY | Internal Medicine | $124.90 |
Prescribed Pulmozyme?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.